Literature DB >> 15791842

Angiogenic potency of bone marrow stromal cells improved by ex vivo hypoxia prestimulation.

Xiaobo Mao1, Qiutang Zeng, Xiang Wang, Linsheng Cao, Zhifeng Bai.   

Abstract

To study the angiogenic potency of hypoxia-prestimulated bone marrow stromal cells (BMSCs) when transplanted into acute myocardial infarction models of rats. BMSCs were cultured under hypoxia condition for 24 h. Their expression of VEGF was investigated. The rat acute myocardial infarction models were made by coronary artery ligation and divided into 3 groups at random. In normoxia group, twice-passaged BMSCs were labeled with Bromodeoxyuridine (BrdU) and then implanted into the infarction regions and ischemic border of the recipients in 4 weeks. The rats in hypoxia group were implanted with hypoxia-prestimulated BMSCs. In control group, the model rats received only DMEM medium injection. Six-weeks after AMI, the infarction regions were examined to identify the angiogenesis and the expression of the VEGF. Our results showed that viable cells labeled with BrdU could be identified in the host hearts. The infarction regions in normoxia and hypoxia groups had a greater capillary density and increased VEGF expression than the regions in control group. The capillary density and VEGF expression in hypoxia group were higher than in normoxia group. It is concluded that the enhanced expression of VEGF in BMSCs could be induced by ex vivo hypoxia stimulation. BMSCs implantation promoted the angiogenesis in myocardial infarction tissue via supplying exogenic VEGF. Angiogenic potency of bone marrow stromal cells was improved by ex vivo hypoxia prestimulation though the enhanced VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15791842     DOI: 10.1007/BF02911356

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  5 in total

Review 1.  Mechanisms of angiogenesis and arteriogenesis.

Authors:  P Carmeliet
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

2.  Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases.

Authors:  K Maruyama; Y Mori; S Murasawa; H Masaki; N Takahashi; Y Tsutusmi; Y Moriguchi; Y Shibazaki; Y Tanaka; M Shibuya; M Inada; H Matsubara; T Iwasaka
Journal:  J Mol Cell Cardiol       Date:  1999-03       Impact factor: 5.000

3.  Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner.

Authors:  M Majka; A Janowska-Wieczorek; J Ratajczak; K Ehrenman; Z Pietrzkowski; M A Kowalska; A M Gewirtz; S G Emerson; M Z Ratajczak
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

4.  Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart.

Authors:  E Hashimoto; T Ogita; T Nakaoka; R Matsuoka; A Takao; Y Kira
Journal:  Am J Physiol       Date:  1994-11

5.  Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation.

Authors:  Shinji Tomita; Donald A G Mickle; Richard D Weisel; Zhi-Qiang Jia; Laura C Tumiati; Yasmin Allidina; Peter Liu; Ren-Ke Li
Journal:  J Thorac Cardiovasc Surg       Date:  2002-06       Impact factor: 5.209

  5 in total
  2 in total

1.  Hypoxia enhances the therapeutic potential of superparamagnetic iron oxide-labeled adipose-derived stem cells for myocardial infarction.

Authors:  Jian Wang; Bo Xiang; Ji-Xian Deng; Hung-Yu Lin; Darren H Freed; Rakesh C Arora; Gang-Hong Tian
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

2.  Hypoxia inducible factor-stabilizing bioactive glasses for directing mesenchymal stem cell behavior.

Authors:  Maria M Azevedo; Olga Tsigkou; Rekha Nair; Julian R Jones; Gavin Jell; Molly M Stevens
Journal:  Tissue Eng Part A       Date:  2014-10-02       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.